+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Furazolidone combination therapies for Helicobacter pylori infection in the United States



Furazolidone combination therapies for Helicobacter pylori infection in the United States



Alimentary Pharmacology & Therapeutics 14(2): 211-215



Background: Antibiotic resistance has begun to impair the ability to cure Helicobacter pylori infection. Aim: To evaluate furazolidone as a component of combination therapies for treatment of H. pylori infection in the United States. Methods: Patients with active H. pylori infection received furazolidone combination therapy for 14 days (furazolidone 100 mg and tetracycline 500 mg t.d.s.; omeprazole 20 mg o.d. in the morning and, depending on the pre-treatment antimicrobial susceptibility pattern, 500 mg of metronidazole or clarithromycin t.d.s.). Results: A total of 27 patients received the metronidazole containing combination (cure rate 100%) and seven received the clarithromycin combination (cure rate 86%). Overall the cure rates for intention-to-treat was 97% (95% CI: 85% to 100%). The single failure took the clarithromycin containing combination for only 2 days (per protocol cure rate = 100%). Side-effects were common and led to discontinuation of therapy in 26% of patients. An attempt to eliminate metronidazole and clarithromycin and use furazolidone, tetracycline, and lansoprazole b.d. produced an unsatisfactory cure rate of 72%. Conclusion: Furazolidone combination therapy appears to be effective. Additional studies with different antimicrobial combinations and duration of therapy are warranted.

(PDF emailed within 0-6 h: $19.90)

Accession: 010691179

Download citation: RISBibTeXText

PMID: 10651662

DOI: 10.1046/j.1365-2036.2000.00640.x


Related references

Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. Saudi Journal of Gastroenterology 18(1): 11-17, 2012

Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 13(3): 317-322, March, 1999

A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. Alimentary Pharmacology & Therapeutics. 11(5): 913-917, 1997

Iron deficiency and Helicobacter pylori infection in the United States. American Journal of Epidemiology 163(2): 127-134, 2005

Combination of bismuth subcitrate and furazolidone in eradication therapy for helicobacter pylori. Gastroenterology 102(4 PART 2): A154, 1992

One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Alimentary Pharmacology & Therapeutics 16(4): 793-798, April, 2002

The risk of Helicobacter pylori infection among U.S. military personnel deployed outside the United States. American Journal of Tropical Medicine and Hygiene 52(1): 109-112, 1995

Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. Journal of Infectious Diseases 181(4): 1359-1363, 2000

Helicobacter pylori infection and pathological periodontal conditions among adults in the United States. American Journal of Epidemiology 151(11 Supplement): S15, June 1, 2000

The relationship between periodontal disease attributes and Helicobacter pylori infection among adults in the United States. American Journal of Public Health 92(11): 1809-1815, 2002